Prostate-specific antigen screening, a procedure designed to detect prostate cancer, recently received a failing grade from the U.S. Preventive Services Task Force. That reportĀ has weighed onĀ Intuitive Surgical's (NASDAQ:ISRG) growth, because PSA screenings have been a large driver of prostatectomies, one of the company's flagship procedures. In this video, Motley Fool health care analyst Brenton Flynn dives into the impact this trend is having on the company and where it might find growth in other areas.

Brenton Flynn has no positions in the stocks mentioned above. The Motley Fool owns shares of Intuitive Surgical and MAKO Surgical. Motley Fool newsletter services recommend Intuitive Surgical and MAKO Surgical. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.